PD-L1 expression analysis in tumor samples was available from 135 patients (50.6%), and expression was low (PD-L1 expression 1–49%) in 52 (38.5%), high (PD-L1 ≥ 50%) in 41 (30.4%), and negative (PD-L1 < 1%) in 42 (31.1%). This evidence concerns the gene CD274 and neoplasm.